SCHEMBL3989503

SCHEMBL3989503

O=c1cc[nH]c2ccc(Br)cc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.53
NR4A2 P43354 2/20 0.53
CYP2A6 P11509 1/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
CHEK1 O14757 2/20 0.50
PIM1 P11309 2/20 0.50
FLT3 P36888 2/20 0.50
AURKA O14965 1/20 0.50
DAPK3 O43293 1/20 0.50
JAK2 O60674 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
PAK4 O96013 1/20 0.50
ABL1 P00519 1/20 0.50
NTRK1 P04629 1/20 0.50
CSF1R P07333 1/20 0.50
RET P07949 1/20 0.50
MET P08581 1/20 0.50
PDGFRB P09619 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13512629 0.84 ALDH1A1 (0.63) AHRNR4A2CYP2A6LMNAHPGD
SCHEMBL12338439 0.78 ALDH1A1 (0.65) AHRNR4A2HPGDAURKAALDH1A1
SCHEMBL1885355 0.78 ALDH1A1 (0.71) AHRNR4A2LMNAHPGDCHEK1
SCHEMBL12338438 0.76 ALDH1A1 (0.63) AHRNR4A2HPGDAURKAALDH1A1
SCHEMBL668615 0.76 AHR (0.53) AHRLMNAHPGDALDH1A1GPR84
SCHEMBL6935037 0.76 ALDH1A1 (0.56) NR4A2LMNAHPGDALDH1A1CCR8
SCHEMBL1880534 0.76 PDE10A (0.49) HPGDALDH1A1CCR8HSD17B10KMT2A
SCHEMBL14242737 0.76 NPSR1 (0.53) LMNAHPGDCHEK1ALDH1A1CCR8
SCHEMBL1430366 0.76 ALDH1A1 (0.48) AHRNR4A2PDGFRBPDGFRAFLT1
SCHEMBL20675600 0.73 ALDH1A1 (0.53) LMNAHPGDPIM1DAPK3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617767-B2 Crystalline forms of somatostatin modulators Crinetics Pharmaceuticals, Inc. (US) 2026-05-05 US disclosed
EP-4608808-A1 SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF Basecamp Bio Inc. (KY) 2025-09-03 EP disclosed
US-20240376067-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. 2024-11-14 US disclosed
WO-2024089668-A1 SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF BASECAMP BIO INC. (KY) 2024-05-02 WO disclosed
CN-116377457-A Electrochemical synthesis method of halogenated quinoline-4 (1H) -ketone derivative 桂林理工大学 2023-07-04 CN disclosed
CN-111868049-B Process for preparing somatostatin modulators 克林提克斯医药股份有限公司 2023-06-30 CN disclosed
WO-2023060255-A1 QUINOLONE ALKYL AMINES AS NOVEL SEROTONIN 2A RECEPTOR (5HT2AR) AGONISTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-04-13 WO disclosed
EP-4092018-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. (US) 2022-11-23 EP disclosed
US-20220267295-A1 CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. 2022-08-25 US disclosed
EP-3999509-A1 CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. (US) 2022-05-25 EP disclosed
WO-2019143718-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. (US) 2019-07-25 WO disclosed
US-20190218202-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. 2019-07-18 US disclosed
US-20190218202-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS Crinetics Pharmaceuticals, Inc. 2019-07-18 US disclosed
US-10301305-B2 Heteroaromatic derivatives and their use as pharmaceuticals MUTABILIS (FR) 2019-05-28 US disclosed
EP-3110803-B1 HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS MUTABILIS (FR) 2018-07-11 EP disclosed
US-20170015661-A1 HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS MUTABILIS (FR) 2017-01-19 US disclosed
EP-3110803-A1 HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS Mutabilis (FR) 2017-01-04 EP disclosed
WO-2015128333-A1 HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LABORATOIRE BIODIM (FR) 2015-09-03 WO disclosed
EP-2913330-A1 Condensed derivatives of imidazole useful as pharmaceuticals LABORATOIRE BIODIM (FR) 2015-09-02 EP disclosed
WO-2009060209-A1 6,6-FUSED BICYCLIC AROMATIC COMPOUNDS AND THEIR THERAPEUTI USE ARGENTA DISCOVERY LIMITED (GB) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220267295-A1 CRYSTALLINE FORMS OF SOMATOSTATIN MODULATORS SSTR5, SSTR4, SSTR3 AHR 4209/4885NR4A2 2182/4885CYP2A6 3305/4885
US-12617767-B2 Crystalline forms of somatostatin modulators IAPP, SSTR2, SSTR3 AHR 4035/4885NR4A2 1782/4885CYP2A6 3147/4885
US-20190218202-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS SSTR5, SSTR4, SSTR2 AHR 3334/4885NR4A2 2897/4885CYP2A6 2815/4885
US-20240376067-A1 PROCESS OF MAKING SOMATOSTATIN MODULATORS SSTR5, SSTR4, SSTR2 AHR 3334/4885NR4A2 2897/4885CYP2A6 2815/4885
US-20170015661-A1 HETEROAROMATIC DERIVATIVES AND THEIR USE AS PHARMACEUTICALS MSR1, IFNAR1, NOD2 AHR 32/4885NR4A2 1292/4885CYP2A6 138/4885
US-10301305-B2 Heteroaromatic derivatives and their use as pharmaceuticals MSR1, IFNAR1, NOD2 AHR 32/4885NR4A2 1292/4885CYP2A6 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.